AACR: One year after mammoth lung cancer win, Merck's Keytruda holds its own in tough-to-treat subgroups

AACR: One year after mammoth lung cancer win, Merck's Keytruda holds its own in tough-to-treat subgroups

Source: 
Fierce Pharma
News Tags: 
snippet: 

At last year’s American Association for Cancer Research annual meeting, Merck’s Keytruda-chemo combo stole the spotlight with stellar lung cancer data. And this year, the company was back to show the regimen's results held up in historically tough-to-treat patient groups.